US › Healthcare

Pharming Group NV (PHAR)

US · Healthcare · Biotechnology

$10.78+1.70%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$90.2M

Revenue YoY

-3.2%

Net profit

$1.6M

Profit YoY

-65.1%

EPS

$0.02

EPS estimate

$0.20

Net margin

1.8%

EPS came in at 0.02 against a street estimate of 0.20 — a miss of 90.0%.

Key statistics

Market cap

$750.2M

P/E

75.7

Forward P/E

196.1

P/B

2.76

Book value

$3.82

EPS (TTM)

$0.14

52-week high

$21.34

52-week low

$9.62

50-day MA

$12.00

200-day MA

$14.91

Beta

0.07

Analyst view

Analysts rate Pharming Group NV a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $34.35.

Shareholding

Institutions

0.14%

Largest institutional holders

Fund	Stake
MAC Alpha Capital Management, LP	3.04%
Silverberg Bernstein Capital Management LLC	0.06%
Crossmark Global Holdings, Inc.	0.02%
Morgan Stanley - Brokerage Accounts	0.02%
SmartHarvest Portfolios, LLC	0.01%
Citadel Advisors Llc	0.01%
Knoll Capital Management LP	0.01%
Goss Wealth Management LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pharming Group NV — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.